Highlights Korro Bio, Inc.

Equities

KRRO

US5009461089

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
52.32 ^USD	-3.13%		-14.22%	+9.16%

Apr. 24	Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	MT
Apr. 24	Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency	Dec. 07	CI
Korro Bio, Inc. completed the acquisition of Frequency Therapeutics, Inc. from a group of shareholders.	Nov. 02	CI
Frequency Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Frequency Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Frequency Therapeutics to Merge With Korro Bio in All-Stock Deal; Shares Rise Pre-Bell	23-07-14	MT
Korro Bio, Inc. entered into a definitive merger agreement to acquire Frequency Therapeutics, Inc. from a group of shareholders in a reverse merger transaction.	23-07-13	CI
Frequency Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
FREQUENCY THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-10	AQ
Frequency Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
Frequency Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-10	CI
Frequency Therapeutics, Inc. Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss	23-02-13	CI
Frequency Therapeutics, Inc. Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss	22-12-15	CI
Frequency Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Frequency Therapeutics, Inc. Completes Enrollment of Phase 2B Study of FX-322 for the Treatment of Sensorineural Hearing Loss	22-10-12	CI
Frequency Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-09	CI
Frequency Therapeutics, Inc. Enters into Sublease Agreement with Saliogen Therapeutics, Inc	22-07-12	CI
Frequency Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-04	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Korro Bio, Inc.

Equities

KRRO

US5009461089

Highlights

Filters